uniQure (NASDAQ:QURE) Director Sells $856,890.84 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 31,434 shares of the company’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $27.26, for a total transaction of $856,890.84. Following the sale, the director owned 40,145 shares of the company’s stock, valued at approximately $1,094,352.70. The trade was a 43.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

uniQure Stock Down 2.3%

QURE opened at $30.12 on Thursday. uniQure N.V. has a 12 month low of $5.50 and a 12 month high of $71.50. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The business’s 50-day moving average price is $42.80 and its 200-day moving average price is $24.54. The company has a market cap of $1.65 billion, a P/E ratio of -7.68 and a beta of 0.59.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $4.46 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. On average, equities analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Institutional Investors Weigh In On uniQure

Institutional investors and hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC bought a new stake in shares of uniQure during the 3rd quarter valued at about $355,000. CI Investments Inc. bought a new position in uniQure in the third quarter worth about $2,769,000. Monashee Investment Management LLC purchased a new stake in uniQure in the third quarter worth about $2,335,000. Rafferty Asset Management LLC lifted its holdings in uniQure by 20.4% in the third quarter. Rafferty Asset Management LLC now owns 82,856 shares of the biotechnology company’s stock worth $4,836,000 after buying an additional 14,049 shares during the period. Finally, Westfield Capital Management Co. LP bought a new stake in uniQure during the 3rd quarter valued at approximately $223,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

QURE has been the topic of several recent analyst reports. Stifel Nicolaus raised their target price on shares of uniQure from $30.00 to $65.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Royal Bank Of Canada dropped their price target on shares of uniQure from $65.00 to $45.00 and set an “outperform” rating for the company in a research report on Monday, November 3rd. Cantor Fitzgerald boosted their price objective on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research report on Thursday, September 25th. The Goldman Sachs Group lowered their price objective on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Finally, Benchmark reissued a “buy” rating on shares of uniQure in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $64.42.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.